Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +0.49%11 Equity-to-Asset is 0.66 as of Jun. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Vyome Holdings ranks worse than 51.98% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vyome Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $6.05 Mil. Vyome Holdings's Total Assets for the quarter that ended in Jun. 2026 was $9.18 Mil.
Therefore, Vyome Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.66.
The historical rank and industry rank for Vyome Holdings's Equity-to-Asset or its related term are showing as below:
HIND'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.28 Med: -1.19 Max: 0.66
Current: 0.66
During the past 4 years, the highest Equity to Asset Ratio of Vyome Holdings was 0.66. The lowest was -4.28. And the median was -1.19.
HIND's Equity-to-Asset is ranked worse than 51.98% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs HIND: 0.66
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vyome Holdings Equity-to-Asset Related Terms
Vyome Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HIND vs INTI, AEON, LSTA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Vyome Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vyome Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a Equity-to-Asset of 0.66 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #735 out of 1414 companies in the Biotechnology industry, placing it in the top 52%.
Is Vyome Holdings' Equity-to-Asset too high?
Vyome Holdings' current Equity-to-Asset is 0.66. The Biotechnology industry median Equity-to-Asset is 0.68. Vyome Holdings' value of 0.66 is 2.9% below this industry median. Based on the distribution chart, Vyome Holdings ranks #735 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Equity-to-Asset compare to INTI and AEON?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #735 out of 1414 companies for Equity-to-Asset. This places Vyome Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Vyome Holdings' value of 0.66 is 2.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vyome Holdings's current Equity-to-Asset of 0.66 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vyome Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current Equity-to-Asset is 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Equity-to-Asset of 0.66. The current Equity-to-Asset is 0.66 and 2.9% below the Biotechnology industry median of 0.68. Vyome Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Equity-to-Asset is 0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
